INMD, my valuation analysis
They are expected to make around $1.53 for 2019 and analysts feel $1.76 for 2020. My feeling about the stock is that because they only have one product, albeit in vogue right now, that the PE going forward should not be as high as the average medical supply company receives of around 30-35. I think more like a 25 PE going forward. So based on the analyst estimates, $44 is full value at present IMO. Also there is an expected secondary offering coming, which the rumor is that there will be 20%-25% dilution. Whether true or not, I believe after the run from $34.80 to $44 in 3 sessions, erring on the side of caution is the prudent move.
